Targeting Therapy for B7-H1 Tumors

Technology #2014-207

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Haidong Dong M.D., Ph.D.
Managed By
Leif R. Nelson
Patent Protection
US Patent Pending
US Patent Pending

Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.